A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly.
The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature review was conducted. The majority of the studies identified (9 out of 10) found that PCV13 was cost-effective in adults and/or the elderly. However, these results were based on assumptions that could not always be informed by robust evidence. Key uncertainties included the efficacy of PCV13 against non-invasive pneumonia and the herd immunity effect of childhood vaccination programs. Emerging trial evidence on PCV13 in adults from the Netherlands offers the ability to parameterize future economic evaluations with empirical efficacy data. However, it is important that these estimates are used thoughtfully when they are transferred to other settings.
a School of Public Health and Community Medicine; UNSW Australia ; Sydney , NSW Australia.
S
S
Dirmesropian
J G
JG
Wood
C R
CR
MacIntyre
A T
AT
Newall
D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D009426:Netherlands; D011008:Pneumococcal Infections / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D011018:Pneumonia, Pneumococcal / Q000517:prevention & control; D018074:Vaccines, Conjugate / Q000627:therapeutic use*
C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
PCV13; adults; cost-effectiveness; economic; elderly; pneumococcal conjugate vaccine